Julien Robert-Paganin

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Molecular Dynamics Simulations

Plasmodium Falciparum

Hypertrophic Cardiomyopathy

Top Venues

Nature communications

Nature cardiovascular research

The EMBO journal

This page only lists publications with an associated author ORCID identifier.

Publications

James J Hartman, Darren T Hwee, Julien Robert-Paganin, Chihyuan Chuang, Eva R Chin, Samantha Edell, Ken H Lee, Roshni Madhvani, Preeti Paliwal, Julien Pernier, Saswata Sankar Sarkar, Julia Schaletzky, Kristine Schauer, Khanha D Taheri, Jingying Wang, Eddie Wehri, Yangsong Wu, Anne Houdusse, Bradley P Morgan, Fady I Malik
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nature cardiovascular research 3 (8) (2024)
James J Hartman, Darren T Hwee, Julien Robert-Paganin, Chihyuan Chuang, Eva R Chin, Samantha Edell, Ken H Lee, Roshni Madhvani, Preeti Paliwal, Julien Pernier, Saswata Sankar Sarkar, Julia Schaletzky, Kristine Schauer, Khanha D Taheri, Jingying Wang, Eddie Wehri, Yangsong Wu, Anne Houdusse, Bradley P Morgan, Fady I Malik
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nature cardiovascular research 3 (8) (2024)
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W Schmidt, Hans-Joachim Knölker, Anne Houdusse
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nature communications 15 (1) (2024)
James A Spudich, Neha Nandwani, Julien Robert-Paganin, Anne Houdusse, Kathleen M Ruppel
Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy. The EMBO journal (2024)
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W Schmidt, Hans-Joachim Knölker, Anne Houdusse
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nature communications 15 (1) (2024)
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W Schmidt, Hans-Joachim Knölker, Anne Houdusse
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nature communications 15 (1) (2024)
James J Hartman, Darren T Hwee, Julien Robert-Paganin, Chihyuan Chuang, Eva R Chin, Samantha Edell, Ken H Lee, Roshni Madhvani, Preeti Paliwal, Julien Pernier, Saswata Sankar Sarkar, Julia Schaletzky, Kristine Schauer, Khanha D Taheri, Jingying Wang, Eddie Wehri, Yangsong Wu, Anne Houdusse, Bradley P Morgan, Fady I Malik
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nature cardiovascular research 3 (8) (2024)
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W Schmidt, Hans-Joachim Knölker, Anne Houdusse
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nature communications 15 (1) (2024)
Alessandro Grinzato, Daniel Auguin, Carlos Kikuti, Neha Nandwani, Dihia Moussaoui, Divya Pathak, Eaazhisai Kandiah, Kathleen M Ruppel, James A Spudich, Anne Houdusse, Julien Robert-Paganin
Cryo-EM structure of the folded-back state of human β-cardiac myosin. Nature communications 14 (1) (2023)
Dihia Moussaoui, James P Robblee, Julien Robert-Paganin, Daniel Auguin, Fabio Fisher, Patricia M Fagnant, Jill E Macfarlane, Julia Schaletzky, Eddie Wehri, Christoph Mueller-Dieckmann, Jake Baum, Kathleen M Trybus, Anne Houdusse
Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design. Nature communications 14 (1) (2023)
Dihia Moussaoui, James P Robblee, Daniel Auguin, Elena B Krementsova, Silvia Haase, Thomas C A Blake, Jake Baum, Julien Robert-Paganin, Kathleen M Trybus, Anne Houdusse
Full-length Plasmodium falciparum myosin A and essential light chain PfELC structures provide new anti-malarial targets. eLife 9 (2020)